SCHEMBL3418792

SCHEMBL3418792

CCC(O)c1cccc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP1A2 P05177 1/20 0.50
TSHR P16473 2/20 0.49
KMT2A Q03164 1/20 0.49
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.44
ADRA2A P08913 2/20 0.44
ADRA2B P18089 2/20 0.44
ADRA2C P18825 2/20 0.44
ADRA1D P25100 2/20 0.44
ADRA1A P35348 2/20 0.44
ADRA1B P35368 2/20 0.44
SLC6A4 P31645 1/20 0.44
ACP3 P15309 1/20 0.42
AOC3 Q16853 1/20 0.42
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3929537 1.00 CYP2C9 (0.50) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL6055148 0.89 HPRT1 (0.48) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL6933120 0.87 LMNA (0.48) CYP1A2TSHRKMT2ALMNAGAA
SCHEMBL2734713 0.85 ALDH1A1 (0.47) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL30582816 0.84 TSHR (0.44) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL6313224 0.83 TSHR (0.46) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL22288132 0.83 LMNA (0.42) ALDH1A1CYP1A2TSHRKMT2ALMNA
SCHEMBL7379765 0.82 PPARG (0.46) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL1527192 0.82 ALDH1A1 (0.52) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR
SCHEMBL28707980 0.82 ALDH1A1 (0.52) CYP2C9CYP2C19ALDH1A1CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4728019-A1 A MICROWAVE CARBONIZATION ASSEMBLY AND METHOD FOR EXTRACTING COMPONENTS FROM RUBBER Sable Rubber IP Pty Limited (AU) 2026-04-22 EP disclosed
CN-121800659-A Preparation method of fluoromethane naphthalenyl propanol 四川大学 2026-04-07 CN disclosed
US-20250188376-A1 SUSTAINABLE AVIATION FUELS SARTEC CORPORATION 2025-06-12 US disclosed
WO-2024257019-A1 A MICROWAVE CARBONIZATION ASSEMBLY AND METHOD FOR EXTRACTING COMPONENTS FROM RUBBER Molectra Rubber IP Pty Ltd (AU) 2024-12-19 WO disclosed
CN-117486673-A Method for synthesizing naphthalene group-containing propargyl fluoride compound by using sulfur hexafluoride 国网安徽省电力有限公司电力科学研究院 2024-02-02 CN disclosed
US-20230416266-A1 6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT MERCK SHARP & DOHME LLC 2023-12-28 US disclosed
EP-4247807-A1 6,7-DIHYDRO-PYRANO[2,3-D]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT Merck Sharp & Dohme LLC (US) 2023-09-27 EP disclosed
CN-114956933-A Marker containing isotope oxygen atom and preparation method and application thereof 清华大学 2022-08-30 CN disclosed
CN-111517902-B Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof 清华大学 2022-06-14 CN disclosed
WO-2022109485-A1 6,7-DIHYDRO-PYRANO[2,3-D]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT MERCK SHARP & DOHME CORP. (US) 2022-05-27 WO disclosed
US-5686486-A 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections PHARMACIA & UPJOHN COMPANY (US) 1997-11-11 US disclosed
EP-0788511-A1 CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-08-13 EP disclosed
EP-0603225-B1 PROCESS FOR PRODUCING alpha-CHLOR-METHYLEN-TRIORGANYLPHOSPHORANE DERIVATES BASF AG (DE) 1997-06-04 EP disclosed
WO-1996011210-A1 CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-18 WO disclosed
EP-0682663-A1 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-22 EP disclosed
WO-1994023732-A1 THERAPEUTIC PREPARATIONS CONTAINING CYPRESS TREE EXTRACTS AND METHODS OF USING SAME KAMBOURAKIS MEDICINAL SOLUTIONS PTY. LIMITED (AU) 1994-10-27 WO disclosed
WO-1994018188-A1 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS THE UPJOHN COMPANY (US) 1994-08-18 WO disclosed
EP-0603225-A1 PROCESS FOR PRODUCING -g(a)-CHLOR-METHYLEN-TRIORGANYLPHOSPHORANE DERIVATES. BASF AG (DE) 1994-06-29 EP disclosed
WO-1993005053-A1 PROCESS FOR PRODUCING α-CHLOR-METHYLEN-TRIORGANYLPHOSPHORANE DERIVATES BASF AKTIENGESELLSCHAFT (DE) 1993-03-18 WO disclosed
EP-0498680-A1 New beta-amino-alpha-hydroxycarboxylic acids and their use Sankyo Company Limited (JP) 1992-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416266-A1 6,7-DIHYDRO-PYRANO[2,3-d]PYRIMIDINE INHIBITORS OF KRAS G12C MUTANT KRAS, NRAS, HRAS CYP2C9 1721/4885CYP2C19 1557/4885ALDH1A1 1176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.